Mie University · University Hospital · 講師

Research keywordspancreatic cancer surgery・borderline resectable disease・chemoradiotherapy outcomes・pancreatic biomarkers・robotic pancreatoduodenectomy・biliary neoplasms

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

•  Hayasaki A, Murata Y, Usui M, et al. Clinical Significance of Plasma Apolipoprotein-AII Isoforms as a Marker of Pancreatic Exocrine Disorder for Patients with Pancreatic Adenocarcinoma Undergoing Chemoradiotherapy, Paying Attention to Pancreatic Morphological Changes. Biomed Res Int. 2019 Apr 4;2019:5738614.2019 · 主な業績等
•  Jaseanchiun W, Kato H, Hayasaki A, et al. The clinical impact of portal venous patency ratio on prognosis of patients with pancreatic ductal adenocarcinoma undergoing pancreatectomy with combined resection of portal vein following preoperative chemoradiotherapy. Pancreatology. 2019 Mar;19(2):307-315.2019 · 主な業績等
•  Hayasaki A, Murata Y, Usui M, et al. Clinical Significance of Histological Effect and Intratumor Stromal Expression of Tenascin-C in Resected Specimens After Chemoradiotherapy for Initially Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma. Pancreas. 2018 Apr;47(4):390-399.2018 · 主な業績等
•  Isaji S, Mizuno S, Hayasaki A, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018 Jan;18(1):2-11.2017 · 主な業績等

• 膵癌リスク患者での膵癌早期発見におけるアポリポプロテインAIIの有用性

• Official profile